会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 96. 发明授权
    • Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
    • 较低的剂量强度咪喹莫特配方和用于治疗生殖器和肛周疣的短剂量方案
    • US09078889B2
    • 2015-07-14
    • US14091965
    • 2013-11-27
    • Medicis Pharmaceutical Corporation
    • Michael T. NordsiekJefferson J. Gregory
    • A01N43/42A61K31/44A61K31/4745
    • A61K31/4745A61K9/0014A61K9/06A61K31/44A61K47/10A61K47/12
    • Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
    • 用于局部或透皮递送1异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-(2-甲基丙基)-1H-咪唑并[4,5-c]喹啉-2-酮的药物制剂和方法, 4-胺,即咪喹莫特,以现在由美国食品和药物管理局(FDA)批准的5%咪喹莫特乳膏市售的治疗时间短于治疗的生殖器/肛周疣, 被公开和描述。 更具体地说,低剂量强度的咪喹莫特制剂,以递送有效剂量的咪喹莫特,用于治疗生殖器/肛周疣,具有可接受的安全性和对于患者使用而言比目前由美国食品和药物当前批准的给药方案更短和更方便的给药方案 还公开和描述了用于治疗生殖器/肛周疣的Aldara 5%咪喹莫特乳膏的给药(“FDA”)。